Journal of Endocrinological Investigation

, Volume 4, Issue 4, pp 445–450 | Cite as

Pituitary gigantism in a 31 month old girl: endocrine studies and successful response to hypophysectomy

  • E. A. Espiner
  • T. A. Carter
  • G. D. Abbott
  • P. Wrightson
Case Report


A case of pituitary gigantism occurring in a 31 month old female child is reported. Growth records indicate that the disorder began early in the second yr of life. Apart from her size and history of excessive sweating, there were no characteristic clinical features of endocrinopathy. Elevated and autonomous secretion of GH (60–109 μg/I) and prolactin were corrected by the removal of an eosinophilic pituitary adenoma. In the subsequent 6 yr, despite the presence of immunoreactive GH (4.6–17.3 μg/l), plasma somatomedin was subnormal and the patient showed growth failure which responded normally to exogenous GH therapy. This case, which appears to be the youngest example of verified pituitary gigantism on record, illustrates that a successful outcome can be achieved by surgical ablative therapy.


Gigantism pituitary tumor acromegaly hypophysectomy growth hormone 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Guyda H., Robert F., Colle E., Hardy J. Histologic, ultrastructural and hormonal characterisation of a pituitary tumour secreting both HGH and prolactin. J. Clin. Endocrinol. Metab. 36: 531, 1973.PubMedCrossRefGoogle Scholar
  2. 2.
    Wool M.S., Selenkow H.A. Charcoal dextran radioimmunoassay of human growth hormone. Acta Endocrinol. (Kbh.) 57: 109, 1968.Google Scholar
  3. 3.
    Donald R.A. Application of the coated charcoal separation method to radioimmunoassay of plasma corticotrophin. J. Endocrinol. 41: 499, 1968.PubMedCrossRefGoogle Scholar
  4. 4.
    Donald R.A. Measurement of pituitary hormones: Clinical applications. 1: Luteinising hormone. N.Z. Med. J. 75: 200, 1972.PubMedGoogle Scholar
  5. 5.
    Odell W.D., Parlow A.F., Cargile C.M., Ross G.J. Radioimmunoassay for human FSH physiological studies. J. Clin. Invest. 47: 2551, 1968.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Donald R.A., Espiner E.A., Hodgkinson S.C., Evans K. Measurement of pituitary hormones: Clinical applica tions. 5: Prolactin. N.Z. Med. J. 83: 431, 1976.PubMedGoogle Scholar
  7. 7.
    Donald R.A., Brownlie B.E.W., Espiner E.A., Rutledge D. Measurement of pituitary hormones: Clinical applica tions. 4: TSH. N.Z. Med. J. 78: 204, 1973.Google Scholar
  8. 8.
    Albano J., Ekins R. In Vitro procedures with radio-isotopes in medicine. International Atomic Energy Agency, Vienna, 1970, p. 491.Google Scholar
  9. 9.
    De Moor P., Raskin M., Steeno O. Fluorimetric determination of free plasmatic and urinary A 4,3 keto-11 hydroxycorticoids. Ann. Endocrinol. (Paris) 21: 479, 1960.Google Scholar
  10. 10.
    Drekter I.J., Heisler A., Seism G.R., Stem S., Pearson S., McGavack T.H. Determination of urinary steroids. Preparation of pigment free extracts and simplified procedure for estimation of total 17 ketosteroids. J. Clin. Endocrinol. Metab. 12: 55, 1952.PubMedCrossRefGoogle Scholar
  11. 11.
    Metcalf M.G. A rapid method for measuring 17 hydroxycorticosteroids in urine. J. Endocrinol. 26: 415, 1963.PubMedCrossRefGoogle Scholar
  12. 12.
    Greulich W.W., Pyle D.I. Radiographic atlas of skeletal development of hand and wrist, ed. 2 Stanford University Press California, Stanford, 1959.Google Scholar
  13. 13.
    Silverman F.S. Roentgen standards for size of the pituitary fossa from infancy through adolescence. J. Radiol. Electrol. Med. Nucl. 78: 451, 1957.Google Scholar
  14. 14.
    Cerasi E., Luft R. Insulin response to glucose loading in acromegaly. Lancet 2: 769, 1964.PubMedCrossRefGoogle Scholar
  15. 15.
    Beck P., Schalach D.S., Parker M.L., Kipnis D.M., Daughaday W.H. Correlative studies of GH and insulin plasma concentrations with metabolic abnormalities in acromegaly. J. Lab. Clin. Med. 66: 366, 1965.PubMedGoogle Scholar
  16. 16.
    Avruskin T.W., Sau K., Tang S., Juan C. Childhood acromegaly: Successful therapy with conventional radiation and effects of chlorpromazine on growth hormone and prolactin secretion. J. Clin. Endocrinol. Metab. 37: 380, 1973.PubMedCrossRefGoogle Scholar
  17. 17.
    Lawrence A.M., Kirstens L. Progestins in medical management of active acromegaly. J. Clin. Endocrinol. Metab. 30: 646, 1970.PubMedCrossRefGoogle Scholar
  18. 18.
    Malarkey W.J., Daughaday W.H. Variable response of plasma GH in acromegalic patients treated with medroxyprogesterone acetate. J. Clin. Endocrinol. Metab. 33: 424, 1971.PubMedCrossRefGoogle Scholar
  19. 19.
    Haigler E.D., Hershman J.M., Meador C.K. Pituitary gigantism. Arch. Intern. Med. 132: 588, 1973.PubMedCrossRefGoogle Scholar
  20. 20.
    Lopis S., Rubenstein A.H., Wright A.D. Serum GH and insulin in gigantism. J. Clin. Endocrinol. Metab. 28: 393, 1968.PubMedCrossRefGoogle Scholar
  21. 21.
    Gordon P., Hendricks C.M., Rotin J. Evidence for “big” and “little” components of human plasma and pituitary growth hormone. J. Clin. Endocrinol. Metab. 36: 178, 1973.CrossRefGoogle Scholar
  22. 22.
    Wright D.R., Goodman A.D., Trimble K.D. Studies on “big” growth hormone from human plasma and pituitary. J. Clin. Invest. 54: 1064, 1974.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1981

Authors and Affiliations

  • E. A. Espiner
    • 1
  • T. A. Carter
    • 2
  • G. D. Abbott
    • 2
  • P. Wrightson
    • 3
  1. 1.Department of EndocrinologyThe Princess Margaret HospitalChristchurchNew Zealand
  2. 2.Department of PediatricsChristchurch HospitalNew Zealand
  3. 3.Department of NeurosurgeryAuckland HospitalAucklandNew Zealand

Personalised recommendations